Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double Blind, Placebo Controlled 2-Parts Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD4205 Following Single and Multiple Ascending Dose in Healthy Adult Subjects, and to Assess the Effect of Food on the Pharmacokinetics of AZD4205

Trial Profile

A Phase I, Randomized, Double Blind, Placebo Controlled 2-Parts Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD4205 Following Single and Multiple Ascending Dose in Healthy Adult Subjects, and to Assess the Effect of Food on the Pharmacokinetics of AZD4205

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 4205 (Primary)
  • Indications Autoimmune disorders; Inflammatory bowel diseases; Non-small cell lung cancer; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Acronyms JACKPOT2
  • Sponsors Dizal Pharmaceutical
  • Most Recent Events

    • 27 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
    • 27 Sep 2019 Status changed from recruiting to active, no longer recruiting.
    • 24 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top